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Abstract
A newly discovered gammaretrovirus, termed XMRV, was recently reported to be present in the prostate cancer cell line
CWR22Rv1. Using a combination of both immunohistochemistry with broadly-reactive murine leukemia virus (MLV) anti-
sera and PCR, we determined if additional prostate cancer or other cell lines contain XMRV or MLV-related viruses. Our study
included a total of 72 cell lines, which included 58 of the 60 human cancer cell lines used in anticancer drug screens and
maintained at the NCI-Frederick (NCI-60). We have identified gammaretroviruses in two additional prostate cancer cell lines:
LAPC4 and VCaP, and show that these viruses are replication competent. Viral genome sequencing identified the virus in
LAPC4 and VCaP as nearly identical to another known xenotropic MLV, Bxv-1. We also identified a gammaretrovirus in the
non-small-cell lung carcinoma cell line EKVX. Prostate cancer cell lines appear to have a propensity for infection with murine
gammaretroviruses, and we propose that this may be in part due to cell line establishment by xenograft passage in
immunocompromised mice. It is unclear if infection with these viruses is necessary for cell line establishment, or what
confounding role they may play in experiments performed with these commonly used lines. Importantly, our results
suggest a need for regular screening of cancer cell lines for retroviral ‘‘contamination’’, much like routine mycoplasma
testing.
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Introduction
Xenotropic Murine leukemia virus-Related Virus (XMRV) was
first reported in 2006 as a novel gammaretrovirus found in
prostate tissues from prostate cancer patients [1]. Subsequent
studies failed to reach a consensus on the prevalence of the virus in
prostate cancer, with reported numbers ranging from 0% to
approximately 27% (reviewed in [2,3]). In 2009, it was reported
that the commonly used prostate cancer cell line CWR22Rv1
contains replication competent XMRV, and produces the virus at
high levels in culture [4].
It is not currently known precisely how the CWR22Rv1 cell line
became infected with XMRV. One explanation is that the virus
was in the prostate tumor from which the cell line was established.
If proven, this discovery would support the argument that XMRV
is present in humans, and can establish an infection in the human
prostate. Another explanation could be that the cell line was
infected after the cells were removed from the patient, for
example, during xenotransplantation into immunocompromised
mice (a commonly used and often necessary practice in the
establishment of prostate cancer cell lines). Indeed, recent data
presented by Pathak et. al. at the 17
th Conference on Retroviruses
and Opportunistic Infections (CROI) provide a compelling
argument that XMRV likely originated from recombination
between two separate and defective endogenous MLVs that
infected the CWR22 human cancer cells at some point during the
process of serial passage of the cells by xenograft (see [5] for
review). This xenograft was later used to produce a cell line,
CWR22Rv1, which is cultivated in many laboratories throughout
the world that study prostate cancer. Reports of infection of
human cell lines with animal retroviruses are quite common in the
literature [6,7,8], (reviewed in [9]) and it is well documented to
occur following xenotransplantation of cells and tissues in
immunocompromised mice (reviewed in [10]). There are also
reports of retroviral infection of cell lines that clearly occurred
during passage in culture, as the lines were never passaged in mice
PLoS ONE | www.plosone.org 1 June 2011 | Volume 6 | Issue 6 | e20874[9,11]. Additional potential sources of cell line infection with
retroviruses include laboratory contamination and the use of
retroviral vectors in research [9]. Importantly, there are only rare
examples where retroviral presence in cultured human cells could
be traced back to a true infection of the patient. One well
established example of this is the discovery of the human T-
lymphotropic virus type 1 (HTLV-1) in cultured cells from patients
with T-cell lymphomas [12].
The discovery of XMRV in the CWR22Rv1 cell line prompted
us to interrogate additional prostate cancer cell lines for the
presence of XMRV or other murine gammaretroviruses. If the
source of retroviral infection is not from the prostate cancer
patient, but introduced by passage through animals or laboratory
contamination, then the presence of replication competent
retroviruses in commonly used prostate cancer cell lines for
research could potentially have confounding effects on experi-
mental outcomes.
Materials and Methods
Cell Lines
Source of cell lines and description of cell line tissue microarray
(TMA) construction is provided in the Text S1. All of the cell lines
used were authenticated via short tandem repeat (STR) profiling
of 9 genomic loci with the Powerplex 1.2 system (Promega) before
inclusion in the TMA.
XMRV/MLV Immunohistochemistry (IHC)
Slides containing sections of formalin-fixed paraffin-embedded
(FFPE) control cells or TMAs were deparaffinized and steamed for
25 min. in citrate-based unmasking solution for antigen retrieval
(Vector Laboratories). IHC (including positive and negative
controls) with either anti-p30 (MLV30) or anti-gp70 (MLV70)
antisera was performed as previously described [3].
XMRV and MLV PCR
Genomic DNA (gDNA) was extracted from cultured cell pellets
from each of the cell lines used in the TMA using the DNeasy
Blood and Tissue Kit (Qiagen). All DNA was first amplified with
genomic GAPDH PCR primers (GAPgen-F 59-GGGCTCTCCA-
GAACATCATCC-39 and GAPgen-R 59-GTCCACCACTGA-
CACGTTGG-39) to verify the quality of the DNA template.
MLV-specific primer (In-For) as well as the XMRV-specific
reverse primer (Deletion-Rev) were as previously described [13]
withan expected product sizeof 104 bp. The degenerate Pan-MLV
primer sequences were as follows: Pan-MLV-F 59-GCARCCC-
WGGGAGACGTC-39 and Pan-MLV-R 59-AGACRCGCRGC-
GCGGYT-39 with an expected product size of approximately
206 bp (181 bp for XMRV). PCR was carried out in a total volume
of 25 ml (containing 1X PCR buffer, 1.5 mM MgCl2, 200 mM
dNTPs, 400 nM F and R primer, 1U AmpliTaq Gold, Applied
Biosystems) using approximately 100 ng of gDNA for template and
the followingcycling parameters: 95uC for 2 min.; 40 cycles of95uC
for 30 sec., 54uC for 1 min. (Pan-MLV primers) or 64uC for 30 sec.
(XMRV-specific primers), 72uC for 30 sec.; final extension at 72uC
for 7 min. Serial dilution tests of CWR22Rv1 gDNA indicated that
the degenerate Pan-MLV PCR assay had a sensitivity of detecting
virus in down to 0.1 ng of CWR22Rv1 gDNA (equivalent to
,100–200 viral genomes or ,10–20 infected cells [3,4]) and the
XMRV-specific PCR assay was capable of detecting down to 1–2
viral genomes (Figure S1). The difference in sensitivity can likely be
explained in part by the use of degenerate primers for Pan-MLV
PCR.
Long-range PCR and Sequencing of Viral Genomes
Full-length or near full-length viral genomes were amplified
from genomic DNA preparations of the LAPC4, VCaP and
EKVX cell lines and sequenced as described in the Text S1 and
Table S2.
Phylogenetic Analysis.
Full-length genomes from known endogenous MLV sequences
[14] and the virus genomes isolated from LAPC4, VCaP and
EKVX were aligned using ClustalW. Based on the alignment, a
neighbor-joining tree was generated using the default settings of
MEGA version 5 (MEGA 5) [15].
Infectivity Assay
Cell line supernatants were collected after 24 hr. culture and
filtered through a 0.45 mm filter. The infectivity assay uses iGLuc-
DERSE cells, a 293 mCAT based cell line that produces the
Gaussia Luciferase (GLuc) enzyme only after infection with a
replication-competent MLV. iGLuc-DERSE cells were seeded at
3.5610 ˆ4 cells/well in a 12-well plate. Cells were treated with
20 mg/ml DEAE-dextran for 30 min. DEAE-dextran was then
removed and cells were rinsed with media. Next, 500 ml of each
supernatant was added to the iGLuc-DERSE cells in triplicate.
Cells were incubated for 3 hr. and 400 ml of additional media was
added. Two and three days after infection, 10 ml of the media from
each well was assayed for luciferase activity. At 3 days after
infection, cells were passaged. Two days after cell passage,
luciferase activity was measured again. Cells were passaged for a
total of 13 days. Further details of the cell line will be given in a
future publication.
Vectorette PCR
Vectorette PCR was performed as previously described [16].
Briefly, 2 mg of genomic DNA was digested overnight at the
appropriate temperature with the following restriction enzymes:
AseI, BspHI, BstYI, HindIII, NcoI, and PstI. Vectorette oligos were
then annealed overnight at 4uC at a concentration of 1 mM using
T4 DNA ligase (New England Biolabs). Vectorette PCR was
conducted using a virus-specific forward primer (either Virus-vec-
F1 59-GACTGAGTCGCCCGGGTACC-39, or Virus-vec-F2 59-
CGCTTCTCGCTTCTGTAACCGCG-39, both in the 39 LTR
in nucleotide position 8525 and 8437 of Xmv43, respectively) and
a vectorette-specific reverse primer (59-CTCTCCCTTCTCGA-
ATCGTAA-39). PCR products were gel purified and cloned into
the pCRH2.1-TOPO vector (Invitrogen). Transformed bacterial
colonies were chosen at random for sequencing.
Results
LAPC4, VCaP and EKVX cancer cell lines are infected with
a murine leukemia virus which is not XMRV
As an initial screen for murine gammaretroviruses in human cell
lines, we utilized a tissue microarray (TMA) containing a total of
72 cell lines, which included 58 of the 60 human cancer cell lines
used in anticancer drug screens and maintained at the NCI-
Frederick (NCI-60) (Table S1). As shown in Figure 1A, IHC with
broadly reactive antisera for Moloney murine leukemia virus (Mo-
MLV) p30
CA (MLV30) or gp70
SU (MLV70) [3] identified three
prostate cancer cell lines (CWR22Rv1, LAPC4 [17], VCaP [18])
as positive for virus. While CWR22Rv1 was previously reported to
be infected with replication competent XMRV [4], LAPC4 and
VCaP are not known to contain retroviruses. Interestingly, in a
previous study, cell culture media from VCaP was anecdotally
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small-cell lung carcinoma cell line, EKVX, as being positive for
virus.
We next used a PCR-based assay to determine whether
LAPC4, VCaP and EKVX are infected with XMRV. As shown
in Figure 1B, PCR with degenerate pan-MLV primers (designed
to broadly amplify MLV species) identified a positive product as
expected for CWR22Rv1, LAPC4, VCaP and EKVX. Also as
expected based on IHC results, PCR with the degenerate MLV
primers was negative for the prostate cancer cell lines DU145,
LNCaP and PC3. PCR with primers that span a 24 nucleotide
deletion contained in the genome of XMRV, but not in any
other known MLVs [13] was only positive for CWR22Rv1
(Figure 1B), indicating that the virus(es) present in the remaining
cell lines that were positive by IHC are not XMRV. The
complete results of IHC and PCR on the 72 cell lines are shown
in Table S1. To control for the possibility that positive PCR
results may have been due to mouse DNA contamination, we
tested all positive cell lines with a PCR assay for mouse
intracisternal A particle (IAP) as previously described [19]. As
shown in Figure S2, none of the cell lines were found to be
positive for contaminating mouse DNA. The IAP assay has
previously been shown to be highly sensitive for mouse DNA,
and to out-perform PCR-based assays for mouse mitochondrial
DNA (mtDNA) [19].
Viral genome sequencing, phylogenetic analysis and
integration site mapping
In order to determine the identity of the viruses present in
LAPC4, VCaP and EKVX, we performed long-range PCR and
sequencing as described in the Text S1. An 8,046 nucleotide
sequence (GenBank Accession #JF908817) obtained from EKVX
clustered with a xenotropic MLV group in phylogenetic analysis,
but was not identical to any MLVs for which the full-length
genomic sequence is known (Figure 2, Supporting Figure S3). This
sequence was also determined in NCBI BLAST database searches
to be 98% similar to a retrovirus previously isolated from the DG-
75 B-lymphoblastoid cell line [20], and identical to partial pol and
env sequences isolated from EKVX in another recent study [8].
For LAPC4 and VCaP, vectorette PCR was performed to
determine viral integration sites and the 59 and 39 ends of the viral
genomes. Nearly identical (99% similar) viral genomes 8,657
nucleotides in length (GenBank Accession #JF908815, JF908816)
were sequenced from the LAPC4 and VCaP cell lines. NCBI
BLAST and Ensembl database searches revealed an almost perfect
match (99%) to a sequence contained on Chromosome 1 of the
C57BL/6J mouse genome sequence (nucleotide position
172871652–172880308). This location maps to a known murine
xenotropic gammaretroviral provirus termed Bxv-1 (or XMV43)
[21]. Phylogenetic analysis also revealed that the LAPC4 and
VCaP viruses are phylogenetically identical to Bxv-1 (Figure 2,
Figure 1. LAPC4, VCaP and EKVX cancer cell lines are infected with a murine leukemia virus which is not XMRV. (A) Examples of MLV-
negative (DU145) and positive (CWR22Rv1, LAPC4, VCaP and EKVX) cancer cell lines stained with MLV30 and MLV70 antisera. (B) Positive staining in
LAPC4, VCaP and EKVX does not represent XMRV. Lanes 1–7, PCR with MLV-specific primers (1= CWR22Rv1, 2= LAPC4, 3= VCaP, 4= DU145, 5=
LNCaP, 6= PC3, 7= EKVX), Lanes 8–11, PCR with XMRV-specific primers (8= CWR22Rv1, 9= LAPC4, 10= VCaP, 11= EKVX). Difference in product size
between CWR22Rv1 (lane 1) and LAPC4, VCaP or EKVX (lanes 2,3,7) is due to the XMRV-specific 24-nt deletion [13]. L= molecular weight ladder.
doi:10.1371/journal.pone.0020874.g001
MLV Contamination of Cancer Cell Lines
PLoS ONE | www.plosone.org 3 June 2011 | Volume 6 | Issue 6 | e20874Supporting Figure S3). Bxv-1 is an intact and infectious provirus
and, although commonly used prostate cancer cell lines are not
known to be contaminated with this virus, Bxv-1 is known to be
capable of infecting tumor cells passaged through immune-
compromised mice [22]. We tested the VCaP cell line directly
from ATCC and confirmed that the distributed VCaP is positive
for virus. To confirm that the infection of LAPC4 cells represents
an infection that was present in early passage LAPC4 (as opposed
to contamination from our laboratory), we obtained LAPC4 cells
frozen down in 1998 as well as cells currently grown in the
laboratory (i.e., from 2010) from the C. L. Sawyers lab at
Memorial Sloan Kettering Cancer Center [17]. As shown in
Figure S4, all LAPC4 cells tested from the Sawyers lab were
positive for virus.
To further verify that the LAPC4 and VCaP cell lines are
infected with integrated Bxv-1 provirus, we mapped multiple viral
integration sites in each of these two lines using vectorette PCR
[16]. Interestingly, viral integration sites were identified in the
intronic regions of multiple genes in both LAPC4 and VCaP
(Table 1). No common integration sites were identified between
the two cell lines; however, we expect that the list of integration
sites given in Table 1 is not exhaustive. Select integration sites
were further verified from LAPC4 and VCaP using long-range
PCR and primers that spanned the integration sites (Table 1).
Infected cancer cell lines produce replication competent
virus
To verify that the commonly used prostate cancer cell lines
LAPC4 and VCaP contain integrated and replication-competent
virus, we performed a viral infectivity assay. The indicator cell line,
iGLuc-DERSE cells, will only secrete the Gaussia luciferase enzyme
following infection with a replication-competent MLV. Gaussia
luciferase activity was detected 48 hours after infection of iGLuc-
DERSE cells with supernatant from the CWR22Rv1, LAPC4 and
VCaP cell lines (Figure 3). Interestingly, a triplicate infection of
iGLuc-DERSE cells with supernatant from the EKVX cell line did
not show Gaussia luciferase activity until 13 days (and 3 passages)
after infection (Figure 3). Further, only 2 of the 3 infections showed
luciferase activity above background. Thus, the virus from EKVX
cells apparently has very low infectivity, at least for the iGLuc-
DERSE cell line. No Gaussia luciferase activity was detected from
cells (passaged for a total of 13 days) exposed to supernatant from
the DU145, MycCaP (a mouse prostate cancer cell line obtained
from theC.L.Sawyers lab) orPC3celllines (Figure3).CWR22Rv1
was previously reported to produce replication competent XMRV
[4] but it has not been reported that LAPC4, VCaP and EKVX
produce replication competent virus.
Out of concern that prostate cancer cell lines producing
replication competent viruses could cross-contaminate other cell
lines in our laboratory which are negative for MLVs, we tested
current cultures in our laboratory for the presence of MLVs. We
were surprised to find two instances where MLV-negative cell lines
maintained in the laboratory (DU145, LNCaP) have become
contaminated with MLVs (Figure S5). For example, when these
cell lines were obtained directly from ATCC (LNCaP) or the NCI
(DU145) they were negative for virus, indicating that the lines
were contaminated at some point during culture in the laboratory.
PCR analysis with XMRV-specific primers indicated that the
contaminating virus was likely XMRV, potentially from culture
alongside CWR22Rv1 (data not shown). These results suggest that
if CWR22Rv1 cells are routinely cultured in a typical biomedical
research laboratory setting (e.g. using standard Class II biosafety
cabinets and procedures for cell culture in which two different cell
lines are never present under the hood at the same time), that
XMRV can infect and contaminate other cell lines.
Discussion
Our study demonstrates that prostate cancer cell lines appear to
have a propensity for infection by murine gammaretroviruses. We
propose that this tendency may be due to the fact that most of the
established prostate cancer cell lines were created by passage
through immunocompromised mice. In fact, Bxv-1 is present in
SCID and nude mice and tumor cells passaged through these
animals can become infected with xenotropic MLVs [22].
Although the infection of human cell lines with murine
gammaretroviruses has been previously described in the literature,
what makes our current study particularly important is that prior
to this study it was not known that multiple commonly used
prostate cancer cell lines are contaminated with MLVs. In fact, we
discovered during the course of our study that other cell lines
Figure 2. Phylogenetic analysis of virus genomes from LAPC4, VCaP and EKVX cell lines. The phylogenetic tree represents known
xenotropic MLV sequences. This tree represents only xenotropic MLVs for which the full proviral sequence is known, which is likely only a small
portion of all endogenous xenotropic MLVs present in mice.
doi:10.1371/journal.pone.0020874.g002
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become infected with XMRV in the laboratory.
In concordance with the data provided in the current study, in a
recent study by Hue et. al., which screened 411 human tumor cell
lines from the Catalogue Of Somatic Mutations In Cancer
(COSMIC) collection, EKVX was found to be positive for a
xenotropic MLV-related virus by direct sequencing of viral gag, pol
and env genes [8]. Furthermore, the Hue et. al. study tested all but
14 of the cell lines examined in the current study (with the
exception of LAPC4, LNCaP, PrEC, VCaP, CWR22Rv1, RWPE,
abl, PrSC, C4-2B, 957 E/h, PacMet UT1, MDA-PAC2b, DLD-1
and Hep3B) and likewise found them to be negative for MLV.
Although the authors of the study did not attempt to obtain a full-
length sequence of the virus contaminating EKVX or to
demonstrate that the virus is replication competent, partial pol
and env sequences from the Hue et. al. study (GenBank Accession
#FR670589 and FR670597, respectively) match at 100%
similarity to the near full-length viral sequence obtained in the
present study (GenBank Accession #JF908817). We have now
demonstrated that the virus contained in the EKVX cell line is
replication competent (Figure 3), clusters in phylogenetic analysis
with known xenotropic MLVs (Figure 2, Supporting Figure S3)
and is 99% similar to a retrovirus previously isolated from the DG-
75 B-lymphoblastoid cell line. Like all of the prostate cancer cell
lines found to contain MLVs in the present study, the EKVX cell
line was established by xenograft passage in nude mice [23].
There are several reported examples of retroviral infection
modifying the biological properties of human cell lines. For
example, the in vivo immunogenicity of cell lines has been shown
to be strongly altered following retroviral infection after a single
passage in nude mice [24]. Likewise, xenotropic MLVs acquired in
cell lines used in HIV research after in vivo passage in
immunocompromised mice were shown to alter the biological
properties of HIV-1 [25]. Studies have also shown that MLV tends
to integrate near transcription start sites (within 5 kb upstream or
downstream) of actively transcribed genes [26]. Interestingly, two of
the seven viral integration sites identified for VCaP are within 5 kb
of a transcription start site (Table 1). An integration site located on
Chromosome 1 is located approximately 2 kb downstream of the
transcription start site of the EFCAB2 (EF-hand calcium binding
domain 2) gene. Likewise, an integration site identified on
Chromosome 7 is located approximately 1.4 kb upstream of LFNG
(O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase), a gene
involved in Notch signaling. It is not known what confounding
effects the infection of commonly used prostate cancer cell lines with
replication competent murine gammaretroviruses may have on
experimental outcomes. Interestingly, it has been reported that
XMRV proteins are more abundant in cell culture media of
CWR22Rv1 cells than any human protein [4]. For reasons such as
this, we suggest that cancer cell lines should undergo routine
screening for contaminating MLVs, much like the current practice
of routine testing of cultured cells for mycoplasma.
Supporting Information
Text S1 Supporting methods.
(DOC)
Figure S1 Determining the sensitivity of the Pan-MLV and
XMRV-specific PCR assays. Serial dilutions of CWR22Rv1
Table 1. Integration sites for Bxv-1-like virus infecting LAPC4 and VCaP prostate cancer cell lines.
Line Chromosome Start* Location
LAPC4 3** 3527870 Intron 2–3 of AC026188.1 Novel processed transcript
9 25617692
VCaP 1**{ 245135029 Intron 1–2 of EF-hand calcium binding domain 2 (EFCAB2)
1 234030449
4 71834780 Intron 2–3 of Mps one binder kinase activator-like 1A (MOBKL1A)
7{ 2550730 Intron 2–3 of AC092488.1 Known protein coding
11 85540286
12 124181500 Intron 12–13 of Tectonic family member 2 (TCTN2)
20 12058633
*Based on Ensembl BLAT release 60- Nov 2010.
**Confirmed by PCR amplification and sequencing across integration sites.
{Located within 5 kb upstream or downstream of a known transcription start site.
doi:10.1371/journal.pone.0020874.t001
Figure 3. CWR22Rv1, LAPC4, VCaP and EKVX produce
replication competent virus as indicated by Gaussia luciferase
production in iGLuc-DERSE cells. 10 ml of media was assayed 2 days
after exposure to 24 hr. cell culture supernatant from CWR22Rv1, LAPC4
and VCaP, and 13 days (and 3 passages) after exposure to supernatant
from EKVX, DU145, MycCaP (murine prostate cancer cell line) and PC3.
Red line indicates background luciferase expression as determined by a
mock-infected control. Error bars represent standard error of the mean
for 3 experiments.
doi:10.1371/journal.pone.0020874.g003
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negative) genomic DNA and used as a template for PCR. (A) Pan-
MLV primers (B) XMRV-specific primers. Samples were tested
in duplicate: 1 ng CWR22Rv1 (lane 1–2), 0.1 ng CWR22Rv1
(lane 3–4), 0.01 ng CWR22Rv1 (lane 5–6), 0.001 ng CWR22Rv1
(lane 7–8), negative control (lane 9–10). L= molecular weight
ladder.
(TIF)
Figure S2 Testing MLV-positive cell lines for the presence of
contaminating mouse DNA by PCR assay for IAP. Lane 1=
C57BL/6J mouse genomic DNA (positive control), lane 2=
CWR22Rv1, lane 3= LAPC4, lane 4= VCaP, lane 5= EKVX,
lane 6= negative control. All cell lines tested were negative for
contaminating mouse DNA. L= molecular weight ladder.
(TIF)
Figure S3 Phylogenetic analysis of virus genomes from
LAPC4, VCaP and EKVX cell lines. The phylogenetic tree
represents known endogenous MLV sequences, including poly-
tropic (Pmv), modified polytropic (Mpmv) and xenotropic (Xm)
viruses. This tree represents only endogenous MLVs for which
the full proviral sequence is known, which is likely only a small
portion of all endogenous MLVs present in mice. Exogenous
MLVs (CAS-BR-E, AKV, MLMCG and Friend) are also
included for comparison.
(TIF)
Figure S4 Testing early passage LAPC4 for presence of virus.
The pan-MLV primers described in Figure 1 were used to test
LAPC4 cells from our laboratory (lane 1), early passage LAPC4
frozen down in 1998 from the C. Sawyers lab (lane 2), LAPC4 cells
frozen down in 2010 from the C. Sawyers lab (lane 3), and a mock
DNA extraction negative control (lane 4). All LAPC4 cells
analyzed were positive for virus.
(TIF)
Figure S5 Examples of MLV-negative prostate cancer cell lines
that have become contaminated with MLV during serial passage
by cell culture in the laboratory. Prostate cancer cell lines obtained
directly from the NCI (DU145) or ATCC (LNCaP) are negative
when stained with MLV30 and MLV70 antisera. These lines were
unexpectedly found to be positive for virus after serial passage in
the lab.
(TIF)
Table S1 Complete results of IHC and PCR on 72 human cell
lines.
(DOC)
Table S2 Primers used to sequence viral genomes.
(DOC)
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